- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07662317
Construction of a Prospective Cohort Database for the Perioperative Period of Cardiac Surgery
Cardiovascular disease (CVD) is the leading cause of global morbidity and mortality, with its prevalence increasing significantly from 1990 to 2019. Establishing a comprehensive cardiac surgery database is crucial for exploring perioperative prognostic factors and improving clinical outcomes.
This muti-center, prospective observational study aims to construct a prospective cohort database for perioperative cardiac surgery. We plan to enroll adult patients who undergo cardiac surgery with cardiopulmonary bypass at the Second Affiliated Hospital of Zhejiang University and other hospitals from May 1, 2026 to December 31, 2031. Multi-dimensional perioperative data, including laboratory tests, hemodynamics, intraoperative echocardiography, and perioperative medications, will be collected and integrated, along with epidemiological data, clinical diagnosis and treatment information, multimodal data, and follow-up outcomes. An interconnected big data sharing platform will also be built.
This database will provide a valuable resource for multi-level researches such as perioperative risk assessment, individualized prevention, precise diagnosis and treatment, and therapeutic efficacy monitoring. It will also help optimize surgical and perioperative management, improve the quality of cardiac surgery, and provide evidence for the refinement of China's healthcare system, ultimately enhancing perioperative safety and rehabilitation efficiency of patients.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Min Yan, Doctor
- Telefoonnummer: 15888210247
- E-mail: zryanmin@zju.edu.cn
Studie Locaties
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Werving
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Patients undergoing cardiac surgery from May 1, 2026 to December 31, 2031
Exclusion Criteria:
- Refusal to provide informed consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Perioperative Observation Group
Patients undergoing cardiac surgery with cardiopulmonary bypass during the perioperative period (including, but not limited to, valve surgery, coronary artery bypass grafting, and combined procedures that require cardiopulmonary bypass)
|
Cardiac surgey
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of major adverse cardiac and cerebrovascular events (MACCE)
Tijdsspanne: 4, 12 weeks and 1years after surgery
|
Myocardial infarction; New-onset stroke: new irreversible neurological impairment confirmed by radiological examination or autopsy showing a new cerebral lesion; Death
|
4, 12 weeks and 1years after surgery
|
|
Incidence of Perioperative Transfusion of Allogeneic Blood Products
Tijdsspanne: 30 days after surgery
|
Allogeneic red blood cells, plasma, platelets, and blood coagulation factors
|
30 days after surgery
|
|
Amount of Allogeneic Blood Products Transfused During the Perioperative Period
Tijdsspanne: 30 days after surgery
|
Allogeneic red blood cells, plasma, platelets, and blood coagulation factors
|
30 days after surgery
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidentie van ongeplande heropname in het ziekenhuis binnen 4 en 12 weken na operatie
Tijdsspanne: 4 en 12 weken na de operatie
|
Ongeplande heropname in het ziekenhuis
|
4 en 12 weken na de operatie
|
|
Incidence of perioperative myocardial infarction
Tijdsspanne: 4, 12 weeks and 1years after surgery
|
Myocardial infarction
|
4, 12 weeks and 1years after surgery
|
|
Incidence of New-onset stroke
Tijdsspanne: 4, 12 weeks and 1years after surgery
|
New-onset stroke: new irreversible neurological impairment confirmed by radiological examination or autopsy showing a new cerebral lesion
|
4, 12 weeks and 1years after surgery
|
|
Incidence of death
Tijdsspanne: 4, 12 weeks and 1years after surgery
|
death
|
4, 12 weeks and 1years after surgery
|
|
Incidence of acute kidney injury
Tijdsspanne: 7days after suegery
|
acute kidney injury was defined by guidelines of kindey disease:improving global outcomes(KIDGO)
|
7days after suegery
|
|
Incidence of infectious complications
Tijdsspanne: 4, 12 weeks and 1years after surgery
|
Infectious complications include, but are not limited to, pneumonia, surgical site infection, etc.
|
4, 12 weeks and 1years after surgery
|
|
Length of hospital stay
Tijdsspanne: Through patients discharge, an average of 7 days after surgery
|
Length of hospital stay
|
Through patients discharge, an average of 7 days after surgery
|
|
Hospitalization costs
Tijdsspanne: Through patients discharge, an average of 7 days after surgery
|
Hospitalization costs
|
Through patients discharge, an average of 7 days after surgery
|
|
Quality of life scores
Tijdsspanne: at 4, 12 weeks and 1 years after surgery
|
Quality of life was assessed using the EuroQol Five-Dimensional Questionnaire (EQ-5D) EuroQol Five-Dimensional Questionnaire (EQ-5D): The EQ-5D includes a visual analog scale (EQ-VAS) ranging from 0 to 100, where higher scores indicate better health status. |
at 4, 12 weeks and 1 years after surgery
|
|
Quality of life scores
Tijdsspanne: at 4, 12 weeks and 1 years after surgery
|
Quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Kansas City Cardiomyopathy Questionnaire (KCCQ): The KCCQ consists of 23 items that quantify the following domains: physical limitations, symptoms (including symptom frequency, severity, and change over time), self-efficacy, social function, and quality of life. The total score ranges from 0 to 100, with higher scores representing better quality of life. |
at 4, 12 weeks and 1 years after surgery
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2026-0345
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .